{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:52:58Z","timestamp":1788789178246,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006370","name":"Small Business Innovation Research","doi-asserted-by":"publisher","award":["1R44AR075469"],"award-info":[{"award-number":["1R44AR075469"]}],"id":[{"id":"10.13039\/100006370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE-1650604"],"award-info":[{"award-number":["DGE-1650604"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["MD190060"],"award-info":[{"award-number":["MD190060"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-08824"],"award-info":[{"award-number":["DISC2-08824"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC0-13765"],"award-info":[{"award-number":["DISC0-13765"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AR065972"],"award-info":[{"award-number":["T32 AR065972"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 AR052646-07"],"award-info":[{"award-number":["U54 AR052646-07"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS117912"],"award-info":[{"award-number":["R01NS117912"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 AR064327"],"award-info":[{"award-number":["RO1 AR064327"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","award":["MDA635862"],"award-info":[{"award-number":["MDA635862"]}],"id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.omtm.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T12:07:58Z","timestamp":1686571678000},"page":"90-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-6402","authenticated-orcid":false,"given":"Michael R.","family":"Emami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.","family":"Farahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Felgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April D.","family":"Pyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Armando","family":"Villalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.06.002_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2021.01.012","article-title":"Challenges at the Crossroads: Myopathy Trials in 2020 Hindsight","volume":"29","author":"Greer","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib2","doi-asserted-by":"crossref","first-page":"814174","DOI":"10.3389\/fneur.2021.814174","article-title":"Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence","volume":"12","author":"Manini","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.omtm.2023.06.002_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In\u00a0Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/jcm10040820","article-title":"Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy","volume":"10","author":"Fortunato","year":"2021","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omtm.2023.06.002_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"231","author":"Chand","year":"2021","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.omtm.2023.06.002_bib6","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy","volume":"44","author":"Day","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.omtm.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal Thrombotic Microangiopathy Case following Adeno-Associated Viral SMN Gene Therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtm.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/JLB.3MIR0220-270R","article-title":"Complement: Bridging the innate and adaptive immune systems in sterile inflammation","volume":"108","author":"Lo","year":"2020","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.omtm.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.omtm.2017.07.004","article-title":"Non-clinical Safety and Efficacy of an AAV2\/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI. Molecular therapy","volume":"6","author":"Ferla","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.06.002_bib10","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","article-title":"Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5(ch) and AAV1","volume":"25","author":"Majowicz","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.06.002_bib12","first-page":"1","article-title":"SGT-001 Microdystrophin gene therapy for Duchenne muscular dystrophy","volume":"28","author":"Gonzalez","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib13","first-page":"1","article-title":"Safety and tolerability of PF-06939926 in ambulatory boys with Duchenne muscular dystrophy: a phase 1b multicenter, open-label, dose ascending study","volume":"28","author":"Moorehead","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib14","doi-asserted-by":"crossref","first-page":"999021","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.06.002_bib15","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2023.06.002_bib16","first-page":"1","article-title":"Characterization of acute toxicity after high-dose systemic adeno-associated virus in nonhuman primates, including impact of vector characteristics","volume":"29","author":"Hordeaux","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/hum.2021.116","article-title":"Biodistribution and Tolerability of AAV-PHP.B-CBh-SMN1 in Wistar Han Rats and Cynomolgus Macaques Reveal Different Toxicologic Profiles","volume":"33","author":"Palazzi","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.omtm.2023.06.002_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2023.06.002_bib20","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood-2019-123666","article-title":"Co-Prevalence of Pre-Existing Immunity to Different Serotypes of Adeno-Associated Virus (AAV) in Adults with Hemophilia","volume":"134","author":"Rajavel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.06.002_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations. Molecular therapy","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.06.002_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.omtm.2021.05.012","article-title":"Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-\u03b3 ELISpot method. Molecular therapy","volume":"22","author":"Patton","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.06.002_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CDLI.8.5.871-879.2001","article-title":"Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus","volume":"8","author":"Smith","year":"2001","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.omtm.2023.06.002_bib24","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1126\/science.1058867","article-title":"Preferential localization of effector memory cells in nonlymphoid tissue","volume":"291","author":"Masopust","year":"2001","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.omtm.2023.06.002_bib25","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2019.01787","article-title":"Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination","volume":"10","author":"Palm","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.06.002_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2023.06.002_bib27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015855118","article-title":"Primate innate immune responses to bacterial and viral pathogens reveals an evolutionary trade-off between strength and specificity","volume":"118","author":"Hawash","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.06.002_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JND-170218","article-title":"Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR\/Cas9 Gene Editing Therapy","volume":"4","author":"Young","year":"2017","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2023.06.002_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/4743","article-title":"Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector","volume":"5","author":"Herzog","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.06.002_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.gt.3302144","article-title":"Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity","volume":"11","author":"Zhang","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1073\/pnas.0408782102","article-title":"Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery","volume":"102","author":"Davies","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.06.002_bib34","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/pmic.200600926","article-title":"Proteome-wide analysis of the serological response to vaccinia and smallpox","volume":"7","author":"Davies","year":"2007","journal-title":"Proteomics"},{"key":"10.1016\/j.omtm.2023.06.002_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/fmb.09.127","article-title":"Defining the humoral immune response to infectious agents using high-density protein microarrays","volume":"5","author":"Vigil","year":"2010","journal-title":"Future Microbiol."},{"key":"10.1016\/j.omtm.2023.06.002_bib36","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in\u00a0vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.06.002_bib37","doi-asserted-by":"crossref","first-page":"675897","DOI":"10.3389\/fimmu.2021.675897","article-title":"Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes","volume":"12","author":"Hamilton","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.06.002_bib38","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.06.002_bib39","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1126\/science.1187029","article-title":"Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3","volume":"329","author":"Sasai","year":"2010","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.omtm.2023.06.002_bib40","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood-2012-02-410936","article-title":"Pivotal role of plasmacytoid dendritic cells in inflammation and NK-cell responses after TLR9 triggering in mice","volume":"120","author":"Guillerey","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.06.002_bib42","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00002371-200411000-00006","article-title":"Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist","volume":"27","author":"Krieg","year":"2004","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2023.06.002_bib43","doi-asserted-by":"crossref","first-page":"e0146326","DOI":"10.1371\/journal.pone.0146326","article-title":"Proinflammatory Stimulation of Toll-Like Receptor 9 with High Dose CpG ODN 1826 Impairs Endothelial Regeneration and Promotes Atherosclerosis in Mice","volume":"11","author":"Krogmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2023.06.002_bib44","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1182\/blood-2011-10-388579","article-title":"Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates","volume":"119","author":"Kwissa","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.06.002_bib45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/exd.12603","article-title":"CpGB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin","volume":"24","author":"Mathes","year":"2015","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.omtm.2023.06.002_bib46","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1743-422X-10-74","article-title":"A survey of ex\u00a0vivo\/in\u00a0vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype","volume":"10","author":"Ellis","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.omtm.2023.06.002_bib47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.omtm.2023.06.002_bib48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/intimm\/12.4.547","article-title":"Stimulation of Fc gamma R receptors induces monocyte chemoattractant protein-1 in the human monocytic cell line THP-1 by a mechanism involving I kappa B-alpha degradation and formation of p50\/p65 NF-kappa B\/Rel complexes","volume":"12","author":"Alonso","year":"2000","journal-title":"Int. Immunol."},{"key":"10.1016\/j.omtm.2023.06.002_bib49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/0192623311428478","article-title":"Crosstalk between complement and toll-like receptors","volume":"40","author":"Song","year":"2012","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtm.2023.06.002_bib50","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.4049\/jimmunol.155.10.4861","article-title":"Triggering of complement receptors CR1 (CD35) and CR3 (CD11b\/CD18) induces nuclear translocation of NF-kappa B (p50\/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells","volume":"155","author":"Thieblemont","year":"1995","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2023.06.002_bib51","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human Immune Responses to Adeno-Associated Virus (AAV) Vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2023.06.002_bib52","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.06.002_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction. Molecular therapy","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2023.06.002_bib54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.virol.2008.01.033","article-title":"Antibody-dependent enhancement of adeno-associated virus infection of human monocytic cell lines","volume":"375","author":"Mori","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2023.06.002_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-61737-982-6_1","article-title":"Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles","volume":"709","author":"Himeda","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2023.06.002_bib56","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/sj.gt.3301602","article-title":"Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters","volume":"8","author":"Weeratna","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JND-190426","article-title":"Advancements in AAV-mediated Gene Therapy for Pompe Disease","volume":"7","author":"Salabarria","year":"2020","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2023.06.002_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/9780471729259.mca04cs6","article-title":"Isolation of human peripheral blood mononuclear cells (PBMCs)","author":"Lan","year":"2007","journal-title":"Curr Protoc Microbiol"},{"key":"10.1016\/j.omtm.2023.06.002_bib59","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1046\/j.1537-2995.2001.41101268.x","article-title":"Frozen-stored granulocytes can be used for an immunofluorescence test to detect granulocyte antibodies","volume":"41","author":"Nishimura","year":"2001","journal-title":"Transfusion"},{"key":"10.1016\/j.omtm.2023.06.002_bib60","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.ymthe.2022.05.004","article-title":"AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicities","volume":"30","author":"Wright","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib61","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.06.002_bib62","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","article-title":"Development of Novel Micro-dystrophins with Enhanced Functionality","volume":"27","author":"Ramos","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.06.002_bib63","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2023.06.002_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkx356","article-title":"WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012300092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012300092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:54:32Z","timestamp":1778867672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905012300092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":64,"alternative-id":["S232905012300092X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.06.002","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}]}}